BioPorto A/S (CPH:BIOPOR)
Denmark
· Delayed Price · Currency is DKK 1.134
-0.018 (-1.56%)
At close: Dec 5, 2025
BioPorto Revenue
BioPorto had revenue of 10.41M DKK in the quarter ending September 30, 2025, with 7.44% growth. This brings the company's revenue in the last twelve months to 36.56M, up 4.74% year-over-year. In the year 2024, BioPorto had annual revenue of 36.24M with 17.07% growth.
Revenue (ttm)
36.56M
Revenue Growth
+4.74%
P/S Ratio
15.36
Revenue / Employee
761.69K
Employees
48
Market Cap
561.44M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 36.24M | 5.29M | 17.07% |
| Dec 31, 2023 | 30.96M | 1.99M | 6.87% |
| Dec 31, 2022 | 28.97M | 4.72M | 19.44% |
| Dec 31, 2021 | 24.25M | 1.05M | 4.53% |
| Dec 31, 2020 | 23.20M | -3.42M | -12.84% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 315.60B |
| Coloplast | 27.87B |
| Genmab | 24.48B |
| ALK-Abelló | 6.08B |
| Demant | 22.59B |
| H. Lundbeck | 24.08B |
| Zealand Pharma | 9.16B |
| Ambu A/S | 6.04B |
BioPorto News
- 12 days ago - BioPorto A/S raises approximately DKK 43 million in new capital round - Change in number of shares and votes - GlobeNewsWire
- 16 days ago - BioPorto A/S 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 22 days ago - Private placement of 40,438,426 new shares fully subscribed – gross proceeds of approximately DKK 43 million to BioPorto A/S - GlobeNewsWire
- 22 days ago - BioPorto Executes on its Financing Strategy- BioPorto A/S initiates pre-subscribed private placement - GlobeNewsWire
- 4 weeks ago - Pre-announcement of the Key Financial Results for Third Quarter 2025 and Revised Guidance for 2025 - GlobeNewsWire
- 2 months ago - BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented - GlobeNewsWire
- 4 months ago - BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth. - GlobeNewsWire
- 4 months ago - BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth. - Benzinga